FeesSafety
Pluang+

Donnelley Financial reports Q3 2026 net earnings of $21.3M, reversing prior loss, with 5.5% sales growth.

Company Fundamentals
29 Oct 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
Donnelley Financial reports Q3 2026 net earnings of $21.3M, reversing prior loss, with 5.5% sales growth.

Donnelley Financial Solutions posted a net profit of $21.3 million in Q3 2026, a significant turnaround from a $40.9 million loss in the same period last year. The company saw a 5.5% increase in net sales to $185 million, driven by growth in software solutions and capital markets activity. Adjusted EBITDA rose 9.9% with margin expansion, and cash flow improved notably. The company expects continued momentum into Q4, supported by strong software sales and operational efficiencies.

Donnelley Financial Solutions reported a net profit of $21.3 million in Q3 2026, reversing a loss from the previous year. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 29, 2026 17:21 WIB: out of 150 priced US tech stocks, 24 rose and 123 fell. Notable movers include PANW at USD 369.10 with a 6.44% decline and a Pluang order activity of 9% Sell / 91% Buy, NBIS at USD 170.81 down 6.32% with 33% Sell / 67% Buy, and ZS at USD 239.71 down 6.29% with 14% Sell / 86% Buy.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App